METAVIA INC (MTVA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.38-0.72%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge METAVIA INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.753
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.517
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-2.37

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
successful capital raises via debt and equity	The company raised capital through debt and equity offerings in early 2026.	Intact	Failure to raise capital or signs of liquidity distress	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
reduce loss per share	MetaVia cut its loss per share from -$3.69 to -$2.49 in 2026.	Broken	EPS does not improve and remains below -2.49 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
stock price stabilizes above 40% drawdown	A supporting condition in METAVIA INC's published investment case. The stated target is Drawdown from high less than -40%.	Under Pressure	Drawdown worsens beyond -59% or new lows	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 3
2026-08-01	Unavailable	Unavailable	2 / 0
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	3 / 3
2026-08-05	Unavailable	Unavailable	3 / 3
2026-08-06	Unavailable	Unavailable	2 / 0
2026-08-07	Unavailable	Unavailable	2 / 0
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	2 / 0
2026-08-12	Unavailable	Unavailable	2 / 0
2026-08-13	Unavailable	Unavailable	2 / 0
2026-08-14	Unavailable	Unavailable	2 / 0
2026-08-15	Unavailable	Unavailable	2 / 0
2026-08-16	Unavailable	Unavailable	2 / 0
2026-08-17	Unavailable	Unavailable	2 / 0
2026-08-18	Unavailable	Unavailable	2 / 0
2026-08-19	Unavailable	Unavailable	2 / 0
2026-08-20	Unavailable	Unavailable	2 / 0
2026-08-21	Unavailable	Unavailable	2 / 0
2026-08-22	Unavailable	Unavailable	2 / 0
2026-08-23	Unavailable	Unavailable	2 / 0
2026-08-24	Unavailable	Unavailable	2 / 0
2026-08-25	Unavailable	Unavailable	2 / 0
2026-08-26	Unavailable	Unavailable	2 / 0
2026-08-27	Unavailable	Unavailable	2 / 0
2026-08-28	Unavailable	Unavailable	2 / 0
2026-08-29	Unavailable	Unavailable	2 / 0
2026-08-30	Unavailable	Unavailable	2 / 0
2026-08-31	Unavailable	Unavailable	2 / 0
2026-09-01	Unavailable	Unavailable	2 / 0
2026-09-02	Unavailable	Unavailable	2 / 0
2026-09-03	Unavailable	Unavailable	2 / 0
2026-09-04	Unavailable	Unavailable	2 / 0
2026-09-05	Unavailable	Unavailable	2 / 0
2026-09-06	Unavailable	Unavailable	2 / 0
2026-09-07	Unavailable	Unavailable	2 / 0
2026-09-08	Unavailable	Unavailable	2 / 0
2026-09-09	Unavailable	Unavailable	2 / 0
2026-09-10	Unavailable	Unavailable	2 / 0
2026-09-11	Unavailable	Unavailable	2 / 0
2026-09-12	Unavailable	Unavailable	2 / 0
2026-09-13	Unavailable	Unavailable	2 / 0
2026-09-14	Unavailable	Unavailable	2 / 0
2026-09-15	Unavailable	Unavailable	2 / 0
2026-09-16	Unavailable	Unavailable	2 / 0
2026-09-17	Unavailable	Unavailable	2 / 0
2026-09-18	Unavailable	Unavailable	2 / 0
2026-09-19	Unavailable	Unavailable	2 / 0
2026-09-20	Unavailable	Unavailable	2 / 0
2026-09-21	Unavailable	Unavailable	2 / 0
2026-09-22	Unavailable	Unavailable	2 / 0
2026-09-23	Unavailable	Unavailable	2 / 0
2026-09-24	Unavailable	Unavailable	2 / 0
2026-09-25	Unavailable	Unavailable	2 / 0
2026-09-26	Unavailable	Unavailable	2 / 0
2026-09-27	Unavailable	Unavailable	2 / 0
2026-09-28	Unavailable	Unavailable	2 / 0
2026-09-29	Unavailable	Unavailable	2 / 0
2026-09-30	Unavailable	Unavailable	2 / 0
2026-10-01	Unavailable	Unavailable	2 / 0
2026-10-02	Unavailable	Unavailable	2 / 0
2026-10-03	Unavailable	Unavailable	2 / 0
2026-10-04	Unavailable	Unavailable	2 / 0
2026-10-05	Unavailable	Unavailable	2 / 0
2026-10-06	Unavailable	Unavailable	2 / 0
2026-10-07	Unavailable	Unavailable	2 / 0
2026-10-08	Unavailable	Unavailable	2 / 0
2026-10-09	Unavailable	Unavailable	2 / 0
2026-10-10	Unavailable	Unavailable	2 / 0
2026-10-11	Unavailable	Unavailable	2 / 0
2026-10-12	Unavailable	Unavailable	2 / 0
2026-10-13	Unavailable	Unavailable	2 / 0
2026-10-14	Unavailable	Unavailable	2 / 0
2026-10-15	Unavailable	Unavailable	2 / 0
2026-10-16	Unavailable	Unavailable	2 / 0
2026-10-17	Unavailable	Unavailable	2 / 0
2026-10-18	Unavailable	Unavailable	2 / 0
2026-10-19	Unavailable	Unavailable	2 / 0
2026-10-20	Unavailable	Unavailable	2 / 0
2026-10-21	Unavailable	Unavailable	2 / 0
2026-10-22	Unavailable	Unavailable	2 / 0
2026-10-23	Unavailable	Unavailable	2 / 0
2026-10-24	Unavailable	Unavailable	2 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	0	0
2026-06-01	2	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

successful capital raises via debt and equityQualitative condition
reduce loss per sharePublished status: Broken
stock price stabilizes above 40% drawdownPublished status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-91.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

METAVIA INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business whose long-term case depends on clinical programs advancing, not on a record of steady profits. The thesis is in a watch state: management has reported development progress, but recent financial performance is weak and overall confidence is low.

What's priced into METAVIA INC

The evidence snapshot does not include valuation or market-expectation data, so it is not possible to say whether the shares look cheap, fair, or expensive versus peers, or what expectations are already reflected. Recent negative earnings events and a decline in the stock’s price reaction show pressure, but do not establish what the market assumes about future results.

What the fundamentals likely do

Near-term execution risk is elevated, with a 64% estimated chance of an earnings miss next quarter; MTVA also missed earnings in May and August 2026. Over the multi-year view, DA-1726 has reached planned doses in a Phase 1 study, with topline data expected in Q4 2026, while cash increased to $12.6 million by Q2 2026 and management expects it to fund operations through 2026.

What METAVIA INC hinges on

The thesis depends on clinical data and continued progress in DA-1726 and vanoglipel, alongside adequate funding as development continues. Near-term risks include a guidance cut or further weakening in jobs data, while stronger results and guidance from healthcare peers could support sector momentum.